Aviso: para depositar documentos, por favor, inicia sesión e identifícate con tu cuenta de correo institucional de la UCM con el botón MI CUENTA UCM. No emplees la opción AUTENTICACIÓN CON CONTRASEÑA
 

Is there a pharmacodynamic need for the use of continuous versus intermittent infusion with ceftazidime against Pseudomonas aeruginosa? An in vitro pharmacodynamic model

dc.contributor.authorAlou Cervera, Luis
dc.contributor.authorAguilar, Lorenzo
dc.contributor.authorSevillano Fernández, David
dc.contributor.authorGiménez, María José
dc.contributor.authorEcheverría, Olatz
dc.contributor.authorGómez-Lus Centelles, María Luisa
dc.contributor.authorPrieto Prieto, José
dc.date.accessioned2024-07-29T12:07:27Z
dc.date.available2024-07-29T12:07:27Z
dc.date.issued2005-02-01
dc.description.abstractObjectives: In order to explore the pharmacodynamic need for continuous versus intermittent (three times a day) administration of ceftazidime in critically ill patients, a pharmacokinetic computerized device was used to simulate concentrations of ceftazidime in human serum after 6 g/day. Methods: Efficacy was measured as the capability of simulated concentrations over time to reduce initial inoculum against four strains of Pseudomonas aeruginosa. MICs of the strains matched NCCLS breakpoints: one susceptible strain (MIC = 8 mg/L), two intermediate strains (MIC = 16 mg/L) and one resistant strain (MIC = 32 mg/L). C(max) was 119.97+/-2.53 mg/L for intermittent bolus and C(ss) (steady-state concentration) was 40.38+/-0.16 mg/L for continuous infusion. AUC(0-24) was similar for both regimens (approximately 950 mg x h/L). Inhibitory quotients were three times higher for the intermittent administration whereas t > MIC was higher for continuous infusion (100%) versus intermittent administration (99.8%, 69% and 47.6% for the susceptible, intermediate and resistant strains, respectively). Results: Against the susceptible and intermediate strains, no differences were found between both regimens with > or = 3 log10 reduction from 8 to 24 h. Against the resistant strain, only the continuous infusion achieved this bactericidal activity in the same time period, minimizing the differences between resistant and susceptible strains. Significantly higher initial inoculum reduction at 32 h was obtained for the continuous versus the intermittent administration (83.35% versus 38.40%, respectively). Conclusions: These results stress the importance of optimizing t >MIC, even at peri-MIC concentrations, of ceftazidime against resistant strains. Local prevalence of resistance justifies, on a pharmacodynamic basis, electing for continuous infusion versus intermittent administration.
dc.description.departmentDepto. de Medicina
dc.description.facultyFac. de Medicina
dc.description.refereedTRUE
dc.description.sponsorshipGlaxoSmithKline S.A.
dc.description.statuspub
dc.identifier.citationAlou L, Aguilar L, Sevillano D, Giménez MJ, Echeverría O, Gómez-Lus ML, Prieto J. Is there a pharmacodynamic need for the use of continuous versus intermittent infusion with ceftazidime against Pseudomonas aeruginosa? An in vitro pharmacodynamic model. J Antimicrob Chemother. 2005 Feb;55(2):209-13.
dc.identifier.doi10.1093/jac/dkh536
dc.identifier.essn1460-2091
dc.identifier.issn0305-7453
dc.identifier.officialurlhttps://doi.org/10.1093/jac/dkh536
dc.identifier.relatedurlhttps://academic.oup.com/jac/article/55/2/209/856817
dc.identifier.urihttps://hdl.handle.net/20.500.14352/107184
dc.issue.number2
dc.journal.titleJournal of Antimicrobial Chemotherapy
dc.language.isoeng
dc.page.final213
dc.page.initial209
dc.publisherOxford University Press
dc.rights.accessRightsrestricted access
dc.subject.cdu611.02
dc.subject.keywordP. aeruginosa
dc.subject.keywordceftazidime
dc.subject.keywordcontinuous infusion
dc.subject.keywordpharmacodynamics
dc.subject.ucmMicrobiología médica
dc.subject.unesco2414 Microbiología
dc.titleIs there a pharmacodynamic need for the use of continuous versus intermittent infusion with ceftazidime against Pseudomonas aeruginosa? An in vitro pharmacodynamic model
dc.typejournal article
dc.type.hasVersionVoR
dc.volume.number55
dspace.entity.typePublication
relation.isAuthorOfPublication889e4dc3-c630-429e-be0f-7f0df2cff492
relation.isAuthorOfPublication518c916a-df78-48cc-9bf7-6a2aaca7d6a2
relation.isAuthorOfPublicationf7ad336e-4779-4665-9893-44b47bed8a7a
relation.isAuthorOfPublication84cd82de-c5ea-4fed-a347-4ed15fb3bcc8
relation.isAuthorOfPublication.latestForDiscovery889e4dc3-c630-429e-be0f-7f0df2cff492

Download

Original bundle

Now showing 1 - 1 of 1
Loading...
Thumbnail Image
Name:
2005 JAC Alou ceftazidime.pdf
Size:
112 KB
Format:
Adobe Portable Document Format

Collections